Leukemia | CHOP Research Institute


The purpose of this study is to evaluate the efficacy of Cart 19 cells therapy as measured by overall remission rate, which includes Complete Remission and Complete Remission with incomplete blood count recovery assessment in infants to adults.

Published on
Feb 3, 2022
Two patients infused with CAR T-cell therapy one decade ago remain in remission with detectable levels of cancer-fighting cells.
Published on
Nov 30, 2021
The Emerging Innovators in Collaborative Research Program highlights non-faculty researchers.

The overall goals of this study are to find the best dose of bosutinib that we can give safely, and to find out what effects, good and/or bad, bosutinib has on children and adolescents with Chronic Myeloid Leukemia (CML).

Published on
May 19, 2021
CHOP Researchers find the novel mechanistic link by which MNI causes acute myeloid leukemia.

Phase 1 open-label study to estimate the safety, manufacturing feasibility, and efficacy of intravenously administered, lentivirally transduced T cells expressing anti-CD123 in pediatric subjects with relapsed/refractory Acute Myeloid Leukemia.

The Tong laboratory studies cytokine receptor and ubiquitin signaling in hematopoietic stem cells, bone marrow failure, and leukemia.

The Teachey Lab studies perturbations in leukemic cell signal transduction pathways with the aim of identifying targeted cancer inhibitors and immunotherapies that can treat children with high-risk leukemias and autoimmune lymphoproliferative syndrome.

This phase 1/2 study will determine the safety, feasibility, and efficacy of CD33 CART cells following lymphodepleting chemotherapy in patients with acute myeloid leukemia (AML).

The Felix Lab aims to understand the pathobiology of leukemias with KMT2A (MLL) translocations in order to discover better treatments and preventative approaches.